Disc Medicine (NASDAQ:IRON) said its Phase III APOLLO trial of investigational bitopertin met both co-primary endpoints and all secondary endpoints in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), supporting the company’s plan to resubmit a new drug application to the U.S. Food and Drug Administration by the end of the year. Chief Executive […]
Disc Medicine (NASDAQ:IRON) said its Phase III APOLLO trial of investigational bitopertin met both co-primary endpoints and all secondary endpoints in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), supporting the company’s plan to resubmit a new drug application to the U.S. Food and Drug Administration by the end of the year. Chief Executive […]This article was originally published by Daily Political.
Read Full Story on Source Site →
